EXPLORE!

DPP-4 Inhibitors: Effects Beyond Glycemic Control

  791 Views

Dr Sanjay Kalra Karnal, Haryana    27 November 2019

  • Dipeptidyl peptidase 4 (DPP-4) inhibitors play a role in simplifying diabetes management and are featured in international guidelines.
  • DPP-4 inhibitors are associated with a low risk of hypoglycemia, are weight-neutral, have proven cardiovascular safety, have few interactions with co-medication, have no timing or dosing issues and are associated with good compliance.
  • DPP-4 inhibitors have higher efficacy in Asian patients.
  • Glucological approach – DPP-4 inhibitors are given as second-line drug after metformin; as first-line if metformin is contraindicated or not tolerated; and as third-line after metformin + sulfonylurea.

Advantages of DPP-4 inhibitors – The 6E Rubric: Efficacy – effective reduction in HbA1c; Ease of use – no dose titration; Error free – safe; Extra-glycemic effect – reduction in progression of albuminuria and cardiac safety; Elementary investigations – minimum investigations required at screening; Elasticity – can be prescribed at any time of the day.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.